Total Payments
$923,174
2024 Payments
$1,461
Companies
13
Transactions
168
Medicare Patients
6,934
Medicare Billing
$763,351
Payment Breakdown by Category
Research$900,687 (97.6%)
Consulting$16,553 (1.8%)
Other$4,360 (0.5%)
Food & Beverage$1,356 (0.1%)
Travel$160.56 (0.0%)
Education$57.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $900,687 | 133 | 97.6% |
| Consulting Fee | $16,553 | 11 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,360 | 2 | 0.5% |
| Food and Beverage | $1,356 | 19 | 0.1% |
| Travel and Lodging | $160.56 | 2 | 0.0% |
| Education | $57.80 | 1 | 0.0% |
Payments by Type
Research
$900,687
133 transactions
General
$22,487
35 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $594,349 | 74 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $235,155 | 54 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $84,372 | 20 | $0 (2024) |
| Philips Electronics North America Corporation | $7,617 | 6 | $0 (2020) |
| Vertex Pharmaceuticals Incorporated | $1,100 | 2 | $0 (2022) |
| Avadel Specialty Pharmaceuticals, LLC | $111.78 | 1 | $0 (2019) |
| Inspire Medical Systems, Inc. | $98.10 | 1 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $90.77 | 1 | $0 (2018) |
| Resmed Corp | $82.30 | 5 | $0 (2019) |
| Avadel CNS Pharmaceuticals, LLC | $70.67 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,461 | 4 | HARMONY BIOSCIENCES LLC ($1,110) |
| 2023 | $42,390 | 16 | Harmony Biosciences LLC ($35,711) |
| 2022 | $38,979 | 9 | HARMONY BIOSCIENCES LLC ($32,976) |
| 2021 | $336,258 | 40 | Takeda Pharmaceuticals U.S.A., Inc. ($334,908) |
| 2020 | $275,627 | 41 | Takeda Pharmaceuticals U.S.A., Inc. ($259,442) |
| 2019 | $7,677 | 11 | Philips Electronics North America Corporation ($4,657) |
| 2018 | $121,704 | 24 | Jazz Pharmaceuticals Inc. ($120,993) |
| 2017 | $99,078 | 23 | Jazz Pharmaceuticals Inc. ($99,030) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/23/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $125.40 | General |
| Category: NEUROLOGY | ||||||
| 07/24/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $70.67 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 06/02/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $154.86 | General |
| 01/18/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | — | Cash or cash equivalent | $1,110.26 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 • Category: Narcolepsy | ||||||
| 12/21/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $4,000.00 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 12/21/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $3,500.00 | Research |
| Study: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | ||||||
| 12/14/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $1,187.59 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 11/16/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $2,336.00 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 11/01/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Education | In-kind items and services | $57.80 | General |
| Category: INSOMNIA | ||||||
| 10/05/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $4,556.52 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 09/26/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $8,950.00 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 09/07/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $1,665.39 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 07/27/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $1,665.39 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 06/02/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,723.96 | Research |
| Study: A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY • Category: NEUROLOGY | ||||||
| 05/18/2023 | Harmony Biosciences LLC | — | — | Cash or cash equivalent | $7,849.64 | Research |
| Study: An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | ||||||
| 02/22/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY • Category: NEUROLOGY | ||||||
| 02/22/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY • Category: NEUROLOGY | ||||||
| 02/22/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY • Category: NEUROLOGY | ||||||
| 02/22/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY • Category: NEUROLOGY | ||||||
| 01/19/2023 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $98.10 | General |
| Category: NEUROLOGY | ||||||
| 12/22/2022 | HARMONY BIOSCIENCES LLC | — | — | Cash or cash equivalent | $2,453.33 | Research |
| Study: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | ||||||
| 12/15/2022 | HARMONY BIOSCIENCES LLC | — | — | Cash or cash equivalent | $17,985.40 | Research |
| Study: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | ||||||
| 12/14/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $558.33 | General |
| 11/14/2022 | JAZZ PHARMACEUTICALS INC. | SUNOSI (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: SOLRIAMFETOL'S EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO-CONTROLLED STUDY (SHARP): A 5-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CROSSOVER MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION IN PARTICIPANTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA PLUS IMPAIRED COGNITIVE FUNCTION • Category: NEUROLOGY | ||||||
| 11/14/2022 | JAZZ PHARMACEUTICALS INC. | SUNOSI (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: SOLRIAMFETOL'S EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO-CONTROLLED STUDY (SHARP): A 5-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CROSSOVER MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION IN PARTICIPANTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA PLUS IMPAIRED COGNITIVE FUNCTION • Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $309,058 | 26 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF A SINGLE INTRAVENOUS INFUSION DOSE OF TAK-925 IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA | Takeda Pharmaceuticals U.S.A., Inc. | $117,925 | 11 |
| A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 R-2-amino-3-phenylpropylcarbamate Hydrochloride in Subjects With Parkinson's Disease and Excessive Sleepiness | Jazz Pharmaceuticals Inc. | $103,412 | 9 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $85,777 | 24 |
| A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA | Jazz Pharmaceuticals Inc. | $77,725 | 19 |
| A DOSE-BLIND EXTENSION STUDY WITH DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EXPLORE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-994 IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY (NARCOLEPSY TYPE 1) | Takeda Pharmaceuticals U.S.A., Inc. | $73,959 | 10 |
| A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy | Jazz Pharmaceuticals Inc. | $38,612 | 9 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | HARMONY BIOSCIENCES LLC | $32,976 | 4 |
| An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | Harmony Biosciences LLC | $32,211 | 8 |
| HBS-101-CL-001 | Harmony Biosciences LLC | $10,000 | 1 |
| A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | JAZZ PHARMACEUTICALS INC. | $6,524 | 5 |
| A PHASE 4 MULTICENTER OPEN-LABEL SINGLE-ARM STUDY OF SAFETY TOLERABILITY EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | JAZZ PHARMACEUTICALS INC. | $3,845 | 2 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | Harmony Biosciences LLC | $3,500 | 1 |
| TAK-994: RESEARCH ACTIVITIES ACROSS OREXIN PROGRAM | Takeda Pharmaceuticals U.S.A., Inc. | $2,453 | 1 |
| SOLRIAMFETOL'S EFFECT ON COGNITIVE HEALTH IN APNEA PARTICIPANTS DURING A RANDOMIZED PLACEBO-CONTROLLED STUDY (SHARP): A 5-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CROSSOVER MULTICENTER STUDY OF SOLRIAMFETOL IN IMPROVING COGNITIVE FUNCTION IN PARTICIPANTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA PLUS IMPAIRED COGNITIVE FUNCTION | JAZZ PHARMACEUTICALS INC. | $1,600 | 2 |
| An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | HARMONY BIOSCIENCES LLC | $1,110 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,728 | 2,226 | $362,314 | $215,697 |
| 2022 | 10 | 1,610 | 2,153 | $339,444 | $165,337 |
| 2021 | 11 | 1,898 | 2,402 | $366,859 | $185,401 |
| 2020 | 13 | 1,698 | 2,261 | $450,580 | $196,916 |
Total Patients
6,934
Total Services
9,042
Medicare Billing
$763,351
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 749 | 1,077 | $151,837 | $107,501 | 70.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 222 | 279 | $62,322 | $38,661 | 62.0% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 200 | 235 | $70,374 | $31,320 | 44.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 119 | 119 | $35,700 | $16,076 | 45.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 111 | $11,136 | $7,404 | 66.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 201 | 259 | $13,684 | $5,316 | 38.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 86 | 89 | $6,764 | $4,358 | 64.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $9,375 | $4,212 | 44.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 22 | 32 | $1,122 | $849.35 | 75.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 757 | 1,138 | $160,458 | $87,917 | 54.8% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2022 | 161 | 196 | $58,800 | $29,234 | 49.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 82 | 112 | $25,200 | $13,892 | 55.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 170 | 176 | $17,125 | $8,759 | 51.1% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 12 | 12 | $22,284 | $7,117 | 31.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 59 | 59 | $17,700 | $6,366 | 36.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 141 | 185 | $14,060 | $5,261 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 31 | 31 | $11,625 | $4,141 | 35.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 171 | 200 | $10,600 | $1,479 | 14.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 26 | 44 | $1,592 | $1,172 | 73.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 816 | 1,171 | $165,541 | $97,694 | 59.0% |
| 95800 | Study of sleep patterns, including sleep time | Office | 2021 | 147 | 173 | $51,900 | $27,748 | 53.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 117 | 117 | $35,100 | $13,372 | 38.1% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 18 | 18 | $33,426 | $11,013 | 32.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 71 | 81 | $18,225 | $9,645 | 52.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 215 | 268 | $20,524 | $8,725 | 42.5% |
About Dr. Helene Emsellem, MD
Dr. Helene Emsellem, MD is a Neurology healthcare provider based in Potomac, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790720001.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Helene Emsellem, MD has received a total of $923,174 in payments from pharmaceutical and medical device companies, with $1,461 received in 2024. These payments were reported across 168 transactions from 13 companies. The most common payment nature is "" ($900,687).
As a Medicare-enrolled provider, Emsellem has provided services to 6,934 Medicare beneficiaries, totaling 9,042 services with total Medicare billing of $763,351. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Potomac, MD
- Active Since 06/19/2006
- Last Updated 02/29/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1790720001
Products in Payments
- XYWAV (Drug) $10,495
- Wakix (Drug) $4,575
- SUNOSI (Drug) $4,300
- SleepUndivided (Device) $3,161
- (9175) NightBalance Und (Device) $2,960
- NightBalance Und (Device) $1,496
- WAKIX (Drug) $1,110
- Noctiva (Drug) $111.78
- Xyrem (Drug) $101.57
- INSPIRE (Device) $98.10
- Hetlioz (Drug) $90.77
- LUMRYZ (Drug) $70.67
- QUVIVIQ (Drug) $57.80
- AirSense (Device) $43.21
- AirCurve (Device) $39.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.